Long-term data from studies in established relapsing-remitting MS (RRMS)
The original BETAFERON pivotal trial led to the approval of BETAFERON in RRMS [1-3]. In the 16- and 21-year long-term follow-up (LTF) studies, patients who participated in the original BETAFERON pivotal trial were re-evaluated [4,5].
- The 16-year LTF assessed long-term clinical outcomes and explored the relationship between drug exposure and long-term disability. The ascertainment rate in this study was 88% [4,5].
- The 21-year LTF primarily aimed to determine the vital status of the participants of the original BETAFERON pivotal study. The vital status was assessed in 98.4% (366/372) of the original study participants .
Patients enrolled in the original BETAFERON pivotal trial were re-evaluated in the 16- and 21-year long-term follow-up studies [4-6]
- The IFNB Multiple Sclerosis Study Group. Neurology 1993; 43(4): 655-61. Return to content
- Paty DW et al. Neurology 1993; 43(4): 662-5. Return to content
- The IFNB Multiple Sclerosis Study Group. Neurology 1995; 45(7): 1277-85. Return to content
- Ebers G et al. Clin Ther 2009; 31: 1724-36. Return to content
- Goodin DS et al. PLoS ONE 2011; 6(11): e22444.doi:10.1371/journal.pone.0022444. Return to content
- Goodin DS et al. Neurology 2012; 78: 1315-22. Return to content